Last $21.94 USD
Change Today -0.05 / -0.23%
Volume 558.4K
MDCO On Other Exchanges
Symbol
Exchange
Munich
NASDAQ GS
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

medicines company (MDCO) Snapshot

Open
$22.04
Previous Close
$21.99
Day High
$22.38
Day Low
$21.63
52 Week High
01/13/14 - $41.28
52 Week Low
10/14/14 - $19.92
Market Cap
1.4B
Average Volume 10 Days
992.9K
EPS TTM
$-0.21
Shares Outstanding
65.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDICINES COMPANY (MDCO)

medicines company (MDCO) Related Businessweek News

No Related Businessweek News Found

medicines company (MDCO) Details

The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria, including Acinetobacter species; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent for the prevention of platelet activation and aggregation; Oritavancin, an investigational intravenous antibiotic for the treatment of acute bacterial skin related infections; and IONSYS, a pre-registration stage product for the short-term management of acute postoperative pain. The company’s products under development also comprise Fibrocaps, which is used as an aid to stop bleeding during surgery; RPX-602 for the treatment of infections; MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of coronary events in patients with ACS; Carbavance, an antibiotic agent for the treatment of hospitalized patients with bacterial infections; and ALN-PCSsc, a subcutaneously administered RNA interference therapeutic for the treatment of hypercholesterolemia. In addition, it offers acute care generic products for use in the cardiovascular and neurocritical care; and promotes BRILINTA, an oral tablet antiplatelet medicine. The company has collaborations with Alnylam Pharmaceuticals, Inc. and AstraZeneca LP. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

571 Employees
Last Reported Date: 03/3/14
Founded in 1996

medicines company (MDCO) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $793.3K
President, Chief Financial Officer, Treasurer...
Total Annual Compensation: $569.3K
Chief Accounting Officer and Senior Vice Pres...
Total Annual Compensation: $398.2K
Compensation as of Fiscal Year 2013.

medicines company (MDCO) Key Developments

The Medicines Company Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Tax Guidance for 2014

The Medicines Company announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company announced net revenue of $172,401,000 compared to $174,282,000 for the same period a year ago. Loss from operations was $12,651,000 compared to income from operations of $22,773,000 for the same period a year ago. Loss before income taxes was $22,482,000 compared to income before income tax of $23,814,000 for the same period a year ago. Net loss attributable to the company was $16,736,000 compared to $7,793,000 for the same period a year ago. Diluted loss per common share attributable to the company was $0.26 compared to income per share of $0.12 for the same period a year ago. Net income attributable to the company, adjusted was $11,576,000 compared to $29,290,000 for the same period a year ago. Net income per share attributable to the company as adjusted, diluted was $0.18 compared to $0.47 for the same period a year ago. For the nine months, the company announced net revenue of $533,410,000 compared to $502,861,000 for the same period a year ago. Loss from operations was $29,786,000 compared to income from operations of $29,053,000 for the same period a year ago. Loss before income taxes was $33,994,000 compared to income before income tax of $31,337,000 for the same period a year ago. Net loss attributable to the company was $26,889,000 compared to $14,314,000 for the same period a year ago. Diluted loss per common share attributable to the company was $0.42 compared to income per share of $0.24 for the same period a year ago. Net income attributable to the company, adjusted was $54,272,000 compared to $76,497,000 for the same period a year ago. Net income per share attributable to the company as adjusted, diluted was $0.82 compared to $1.29 for the same period a year ago. The company would expect to record a tax benefit of between $11 million and $14 million, and still expect that its cash taxes will be in the range of $3 million to $5 million.

The Medicines Company Publish Results from SOLO II Phase 3 Clinical Trial of ORBACTIV

The Medicines Company announced the publication of the results from the SOLO II Phase 3 clinical trial of ORBACTIV (oritavancin) for injection in the journal Clinical Infectious Diseases. ORBACTIV, is the first and only single dose intravenous antibiotic approved by FDA for the treatment of adults with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused or suspected to be caused by susceptible isolates of designated Gram-positive pathogens. The publication reported that a single, once only, 1,200 mg intravenous dose of ORBACTIV(TM) was non-inferior to twice-daily intravenous dosing of vancomycin given for 7 to 10 days in patients with ABSSSI caused or suspected to be caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). A single 1,200 mg IV dose of ORBACTIV results in efficacy in ABSSSIs that is comparable and statistically non-inferior to vancomycin administered intravenously for 7-10 days. ORBACTIV had a safety profile comparable to vancomycin when monitored for up to 60 days following a single dose, with similar intensity, onset and duration of AEs.

The Medicines Company to Report Q3, 2014 Results on Oct 22, 2014

The Medicines Company announced that they will report Q3, 2014 results at 8:30 AM, US Eastern Standard Time on Oct 22, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDCO:US $21.94 USD -0.05

MDCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $69.83 USD +0.73
CryoLife Inc $10.55 USD +0.05
Eli Lilly & Co $66.05 USD +1.70
GlaxoSmithKline PLC 1,416 GBp +3.50
Medicure Inc C$2.40 CAD +0.03
View Industry Companies
 

Industry Analysis

MDCO

Industry Average

Valuation MDCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.0x
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICINES COMPANY, please visit www.themedicinescompany.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.